Figure 6A shows that Tetlo GSW11-specific T cells were more effective at controlling tumor growth over a period of 40 days than their Tethi counterparts. By combining adoptive T cell transfer with two doses of anti-PD-1 administered on days 3 and 9 (2 and 8 days after transfer), we found that little improvement in therapeutic efficacy was achieved in mice transferred with Tethi, whereas curative responses were achieved for Tetlo as shown in figure 6B. The gene discussed is PDCD1; the disease is neoplasm.